Recursion Pharmaceuticals Inc. stocks have been trading down by -8.72 percent after bearish analyst coverage questioned its AI drug-discovery timeline.
Click Here for a Millionaire's POV on Trading RXRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- RXRX is fading off recent highs, with the stock sliding from above $5 to around $4 on light but steady selling.
- Intraday action shows Recursion Pharmaceuticals Inc. chopping in a tight band near $4, signaling short-term consolidation.
- The latest report shows RXRX with over $545M in cash and relatively low debt, giving the company breathing room.
- Recursion Pharmaceuticals Inc. continues to post heavy losses as it spends aggressively on research and operations.
- Traders are tracking support in the high‑$3s and resistance near $4.60–$5 as key near-term decision zones.
Live Update At 12:32:30 EDT: On Monday, October 12, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending down by -8.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RXRX is a classic high‑burn, high‑cash biotech story. The latest quarter shows Recursion Pharmaceuticals Inc. bringing in roughly $7.3M in total revenue, while running more than $142M in total expenses. That gap matters. It tells traders RXRX is still in build‑out mode, not in harvest mode.
Net loss sits near $131M for the quarter, or about -$0.25 per share. Margins are deeply negative across the board, with EBITDA and EBIT firmly in the red. For traders, that’s normal in early‑stage drug discovery, but it raises the bar for future funding or partnerships.
On the balance sheet, RXRX looks sturdier. Recursion Pharmaceuticals Inc. shows about $545M in cash and equivalents against only about $4.8M in long‑term debt and limited current debt. Liquidity ratios are strong, with a current ratio around 5. That gives RXRX a runway measured in years, not months, even with free cash flow running around -$108M for the quarter.
More Breaking News
- MNDR Stock Whipsaws As Traders Lean Into Volatility
- ITUB Stock Holds Gains As HSBC Downgrade Caps Upside
- LNKS Stock Pops On Heavy Volume As Balance Sheet Shines
- SNAP Stock Eyes Re‑Rating As SPECS AR And Activists Step In
The market is pricing that story at a high price‑to‑sales multiple above 40, signaling traders are paying for potential more than present revenue.
Why Traders Are Watching RXRX Price Levels
RXRX price action over the last few weeks is exactly the kind of grind that tests patience. Recursion Pharmaceuticals Inc. rallied from the mid‑$3s up into the mid‑$4s and briefly pushed above $5 before sliding back. Now RXRX is trapped between support in the upper‑$3s and resistance in the mid‑$4s.
On the daily chart, the recent candles show long upper wicks near days when RXRX tried to hold above $4.80–$5. That’s classic supply. Each push higher met selling, telling short‑term traders that momentum is fading for now. At the same time, every dip toward $3.70–$3.80 has been scooped up, which suggests dip buyers are defending that zone.
Zoom in to the intraday five‑minute chart and you see a tight coil around $3.98–$4.02. RXRX opened near $4.31, sold off into the low $4s, then spent most of the session grinding sideways with tiny candles. That’s indecision. Volume‑weighted action is clustering around $4, turning it into a control point.
For active traders, this setup is simple but important. A clean break and hold above $4.60–$4.80 opens room back toward recent highs. A sustained crack under $3.70 could trigger a flush as swing traders bail. RXRX, with its big cash pile but heavy burn, is a textbook battleground between long‑term biotech bulls and short‑term momentum traders playing the range.
Conclusion
RXRX sits at an interesting crossroads. Fundamentally, Recursion Pharmaceuticals Inc. has what many early‑stage biotechs lack: a large cash cushion and low leverage. Over $545M in cash versus modest debt buys time to keep funding AI‑driven drug discovery and to absorb quarters of deep losses. But the income statement shows the cost of that strategy clearly, with negative margins, heavy R&D spend, and free cash flow well into the red.
On the chart, RXRX is neutral at best in the near term. Price is consolidating around $4 after failing to hold a push toward $5, while the high‑$3s act as a soft floor. Until Recursion Pharmaceuticals Inc. breaks from this band, traders are likely to keep treating it as a range‑bound, short‑term trading vehicle rather than a clean trend.
For active traders, the lessons are straightforward. Respect the volatility, map your levels, and do not fall in love with a story stock that is still years away from clear profitability. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” That mindset dovetails with classic guidance from momentum‑focused educators. As Tim Sykes likes to remind traders, “It’s not about being right, it’s about protecting your trading account so you can stay in the game.” RXRX gives plenty of opportunity for those who follow that rule and cut losses fast.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.